دورية أكاديمية
Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.
| العنوان: | Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections. |
|---|---|
| المؤلفون: | Stewart CL; Moses Cone Hospital, Cone Health, Greensboro, NC, USA., Turner MS; Moses Cone Hospital, Cone Health, Greensboro, NC, USA., Frens JJ; Moses Cone Hospital, Cone Health, Greensboro, NC, USA., Snider CB; Moses Cone Hospital, Cone Health, Greensboro, NC, USA., Smith JR; Moses Cone Hospital, Cone Health, Greensboro, NC, USA. jsmith5@highpoint.edu.; Fred Wilson School of Pharmacy, High Point University, High Point, NC, USA. jsmith5@highpoint.edu. |
| المصدر: | Infectious diseases and therapy [Infect Dis Ther] 2017 Jun; Vol. 6 (2), pp. 277-289. Date of Electronic Publication: 2017 Apr 06. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Publication: 2014- : [Auckland] Adis Original Publication: [London] : Springer Healthcare |
| مستخلص: | Introduction: Oritavancin is a novel lipoglycopeptide approved for acute bacterial skin and skin structure infections. The pharmacokinetic profile and convenient one-time dosing make oritavancin an enticing option for other serious Gram-positive infections requiring prolonged treatment courses. Unfortunately, data for using oritavancin in these populations are limited. Methods: We report ten cases of oritavancin use for invasive Gram-positive infections in our health system, and provide a review of the currently available literature regarding oritavancin therapy for invasive infections. Results: Among the ten patients who received oritavancin, the most common infection was methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia (n = 5, 50%). Other indications for oritavancin use included methicillin-resistant S. aureus (MRSA) bursitis (n = 1, 10%), group B streptococcal bacteremia with native tricuspid valve infective endocarditis (n = 1, 10%), coagulase-negative staphylococcal bacteremia (n = 1, 10%), MSSA deep tissue infection (n = 1, 10%), and enterococcal bacteremia (n = 1, 10%). Oritavancin was well tolerated, and 7/10 (70%) patients were successfully treated. Conclusion: Oritavancin is a potential option for patients with invasive Gram-positive infections. Further study is warranted. |
| References: | Open Forum Infect Dis. 2015 Oct 29;2(4):ofv156. (PMID: 26677455) J Antimicrob Chemother. 2013 Jan;68(1):164-7. (PMID: 22941898) N Engl J Med. 2014 Jun 5;370(23):2180-90. (PMID: 24897083) Diagn Microbiol Infect Dis. 2016 Nov;86(3):303-306. (PMID: 27543378) Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. (PMID: 19106348) Clin Microbiol Infect. 2005 May;11 Suppl 3:22-8. (PMID: 15811021) Clin Infect Dis. 2015 Jan 15;60(2):254-62. (PMID: 25294250) Antimicrob Agents Chemother. 2011 Jul;55(7):3476-84. (PMID: 21537018) Clin Infect Dis. 2011 Feb 1;52(3):e18-55. (PMID: 21208910) Antimicrob Agents Chemother. 2016 Mar 25;60(4):2352-8. (PMID: 26833159) Antimicrob Agents Chemother. 2014 May;58(5):2921-4. (PMID: 24550323) Clin Infect Dis. 2003 Jan 1;36(1):53-9. (PMID: 12491202) Antimicrob Agents Chemother. 2015;59(6):3365-72. (PMID: 25824211) Antimicrob Agents Chemother. 2012 Mar;56(3):1639-42. (PMID: 22183169) Clin Infect Dis. 2004 Jun 15;38(12):1651-72. (PMID: 15227610) Clin Microbiol Rev. 2012 Apr;25(2):362-86. (PMID: 22491776) Infect Control Hosp Epidemiol. 2013 Jan;34(1):1-14. (PMID: 23221186) Antimicrob Agents Chemother. 2009 Oct;53(10):4422-8. (PMID: 19635952) Br J Audiol. 1984 Aug;18(3):179-80. (PMID: 6487853) |
| فهرسة مساهمة: | Keywords: Bacteremia; Extended duration; Lipoglycopeptide; OPAT; Outpatient parenteral antimicrobial therapy; Staphylococci; Staphylococcus aureus |
| تواريخ الأحداث: | Date Created: 20170408 Latest Revision: 20220409 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5446369 |
| DOI: | 10.1007/s40121-017-0156-z |
| PMID: | 28386776 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2193-8229 |
|---|---|
| DOI: | 10.1007/s40121-017-0156-z |